/JSPR
JSPR Stock - Jasper Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.86+0.00%
+$0.00 (+0.00%) • Dec 19
47
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2480.6%upside
Target: $48.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for JSPR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.84 – $1.88
TARGET (TP)$48.00
STOP LOSS$1.71
RISK/REWARD1:307.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.06
52W High$22.98
52W Low$1.39
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-76,239,000 | $-68,861,000 | $-51,196,000 | $-36,833,000 | $-20,683,000 |
| Net Income | $-71,269,000 | $-64,465,000 | $-37,685,000 | $-30,637,000 | $-31,669,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-4.89 | $-6.18 | $-10.33 | $-26.89 | $-183.08 |
Company Overview
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
90%
Hold / Neutral
1
10%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish1 Neutral/Bearish
Price Targets
$51
Average Target
↑ 2651.7% Upside
Now
$4
Low
$51
Average
$90
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 8th 2025 | BMO Capital Markets | Downgrade | Market Perform | $4 |
| July 8th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $5 |
| July 7th 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| July 7th 2025 | William Blair | Downgrade | Market Perform | - |
| February 13th 2025 | UBS | Initiation | Buy | $38 |
| December 6th 2024 | BMO Capital Markets | Initiation | Outperform | $63 |
| September 9th 2024 | JMP Securities | Initiation | Mkt Outperform | $70 |
| July 8th 2024 | BTIG Research | Initiation | Buy | $90 |
| June 27th 2024 | Stifel | Initiation | Buy | $86 |
| May 6th 2024 | H.C. Wainwright | Initiation | Buy | $65 |
| April 3rd 2024 | Evercore ISI | Initiation | Outperform | $65 |
| March 28th 2024 | RBC Capital Mkts | Initiation | Outperform | $70 |
| March 18th 2024 | TD Cowen | Initiation | Outperform | - |
| August 11th 2023 | CapitalOne | Initiation | Overweight | $7 |
Earnings History & Surprises
JSPRBeat Rate
35%
Last 17 quarters
Avg Surprise
-22.0%
EPS vs Estimate
Beats / Misses
6/10
1 met exactly
Latest EPS
$-1.13
Q4 2025
EPS Surprise History
Q1 24
+9.1%
$-1.50vs$-1.65
Q2 24
+18.3%
$-1.03vs$-1.26
Q3 24
+11.0%
$-0.97vs$-1.09
Q4 24
-13.8%
$-1.24vs$-1.09
Q1 25
-27.6%
$-1.62vs$-1.27
Q2 25
-20.5%
$-1.41vs$-1.17
Q3 25
-45.0%
$-1.74vs$-1.20
Q4 25
-11.9%
$-1.13vs$-1.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.79 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-1.01 | $-1.13 | -11.9% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-1.20 | $-1.74 | -45.0% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-1.17 | $-1.41 | -20.5% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-1.27 | $-1.62 | -27.6% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-1.09 | $-1.24 | -13.8% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-1.09 | $-0.97 | +11.0% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-1.26 | $-1.03 | +18.3% | ✓ BEAT |
Q1 2024 | Mar 4, 2024 | $-1.65 | $-1.50 | +9.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-1.50 | $-1.60 | -6.7% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-1.30 | $-1.50 | -15.4% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-1.50 | $-1.60 | -6.7% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-3.70 | $-3.60 | +2.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-3.50 | $-3.20 | +8.6% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-2.90 | $-2.90 | 0.0% | = MET |
Q2 2022 | May 12, 2022 | $-3.60 | $-3.50 | +2.8% | ✓ BEAT |
Q1 2022 | Mar 18, 2022 | $-0.34 | $-0.79 | -132.4% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.28 | $-0.69 | -146.4% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | — | $-0.84 | — | — |
Latest News
Jasper Therapeutics shares are trading higher after the company reported preliminary clinical data from Jasper's ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma.
📈 PositiveBenzinga•Dec 2, 2025, 01:45 PM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 2, 2025, 12:25 PM
Market-Moving News for December 2nd
➖ NeutralBenzinga•Dec 2, 2025, 12:12 PM•Also: ,
Jasper Therapeutics Reports Positive Preliminary Asthma Data For Briquilimab And Concludes BEACON Investigation With No Drug Product Issues
📈 PositiveBenzinga•Dec 2, 2025, 12:02 PM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 2, 2025, 11:55 AM
JSPR stock has given up its prior loss. JSPR shares were trading lower after the company scheduled an investor webinar to present preliminary ETESIAN asthma study data and BEACON study findings.
➖ NeutralBenzinga•Dec 1, 2025, 10:02 PM
JSPR shares are trading lower after the company scheduled an investor webinar to present preliminary ETESIAN asthma study data and BEACON study findings.
➖ NeutralBenzinga•Dec 1, 2025, 09:32 PM
Jasper Therapeutics To Host Investor Webinar On Dec. 2 at 8:00 a.m. ET To Pesent Prelim Data From ETESIAN Study In Asthma And Findings From BEACON Study Investigation
➖ NeutralBenzinga•Dec 1, 2025, 09:31 PM
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $4
➖ NeutralBenzinga•Nov 11, 2025, 03:25 PM
Jasper Therapeutics Q3 EPS $(1.13) Beats $(1.28) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 01:05 PM
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $14
➖ NeutralBenzinga•Sep 22, 2025, 03:00 PM
JMP Securities Maintains Market Outperform on Jasper Therapeutics, Lowers Price Target to $6
➖ NeutralBenzinga•Sep 22, 2025, 01:22 PM
BTIG Maintains Buy on Jasper Therapeutics, Lowers Price Target to $7
📈 PositiveBenzinga•Sep 22, 2025, 09:36 AM
Jasper Therapeutics Announces $30M Public Offering Including 11,670,707 Common Shares At $2.43 Per Share And 675,000 Pre-Funded Warrants At $2.43 Less $0.0001 Per Share Exercise Price
➖ NeutralBenzinga•Sep 19, 2025, 04:53 AM
Jasper Therapeutics shares are trading lower after the company announced a proposed public offering of its common stock.
📉 NegativeBenzinga•Sep 18, 2025, 08:20 PM
Jasper Therapeutics Announces Proposed Underwritten Public Offering Of Its Common Stock; No Financial Terms Disclosed
➖ NeutralBenzinga•Sep 18, 2025, 08:11 PM
Frequently Asked Questions about JSPR
What is JSPR's current stock price?
Jasper Therapeutics, Inc. (JSPR) is currently trading at $1.86 per share. The stock has moved +0.00% today.
What is the analyst price target for JSPR?
The average analyst price target for JSPR is $48.00, based on 1 analyst.
What sector is Jasper Therapeutics, Inc. in?
Jasper Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is JSPR's market cap?
Jasper Therapeutics, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does JSPR pay dividends?
No, Jasper Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
MURA
Mural Oncology plc
$2.04
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to JSPR for comparison